(NDSN) Nordson - Overview
Stock: Dispensers, Coatings, Adhesives, Syringes, Inspection
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.45% |
| Yield on Cost 5y | 1.78% |
| Yield CAGR 5y | 21.94% |
| Payout Consistency | 99.5% |
| Payout Ratio | 32.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.3% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 20.32 |
| Character TTM | |
|---|---|
| Beta | 1.055 |
| Beta Downside | 0.972 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.15% |
| CAGR/Max DD | 0.20 |
Description: NDSN Nordson January 04, 2026
Nordson Corporation (NASDAQ:NDSN) designs, manufactures, and sells precision dispensing and fluid-control systems across three main segments: Industrial Precision Solutions, which serves adhesive and coating applications in disposable goods and roll-to-roll manufacturing; Medical and Fluid Solutions, which provides syringes, cartridges, interventional delivery devices, and cardiovascular consumables; and Advanced Technology Solutions, which delivers high-speed dispensing, gas-plasma treatment, and non-destructive testing equipment for the semiconductor and PCB markets. The company reaches customers through a mix of direct sales, distributors, and field representatives and has operated for more than a century from its Westlake, Ohio headquarters.
Key recent metrics (FY 2024) show revenue of roughly $2.4 billion, a GAAP EPS of $3.50, and an operating margin near 15 %, reflecting steady demand for automation-driven adhesive technologies in automotive, electronics, and medical device production. The segment most sensitive to macro trends is Industrial Precision Solutions, where reshoring of electronics manufacturing and the shift to electric-vehicle architectures are expanding the addressable market for high-precision fluid application. Conversely, the Advanced Technology Solutions line is tied to semiconductor capital-expenditure cycles, which are currently volatile due to geopolitical supply-chain constraints.
For a deeper quantitative view, the ValueRay platform offers granular financial and operational data that can help you benchmark Nordson against peers and assess the sustainability of its growth drivers.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income: 484.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.98 > 1.0 |
| NWC/Revenue: 17.36% < 20% (prev 27.75%; Δ -10.40% < -1%) |
| CFO/TA 0.12 > 3% & CFO 719.2m > Net Income 484.5m |
| Net Debt (1.98b) to EBITDA (866.5m): 2.29 < 3 |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.4m) vs 12m ago -2.06% < -2% |
| Gross Margin: 55.16% > 18% (prev 0.55%; Δ 5460 % > 0.5%) |
| Asset Turnover: 46.85% > 50% (prev 44.82%; Δ 2.02% > 0%) |
| Interest Coverage Ratio: 6.94 > 6 (EBITDA TTM 866.5m / Interest Expense TTM 103.2m) |
Altman Z'' 5.53
| A: 0.08 (Total Current Assets 1.24b - Total Current Liabilities 758.3m) / Total Assets 5.92b |
| B: 0.78 (Retained Earnings 4.60b / Total Assets 5.92b) |
| C: 0.12 (EBIT TTM 716.0m / Avg Total Assets 5.96b) |
| D: 1.57 (Book Value of Equity 4.51b / Total Liabilities 2.87b) |
| Altman-Z'' Score: 5.53 = AAA |
Beneish M -3.08
| DSRI: 0.95 (Receivables 587.8m/594.7m, Revenue 2.79b/2.69b) |
| GMI: 1.00 (GM 55.16% / 55.25%) |
| AQI: 0.99 (AQ_t 0.69 / AQ_t-1 0.70) |
| SGI: 1.04 (Revenue 2.79b / 2.69b) |
| TATA: -0.04 (NI 484.5m - CFO 719.2m) / TA 5.92b) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of NDSN shares?
Over the past week, the price has changed by +5.70%, over one month by +15.15%, over three months by +26.29% and over the past year by +36.75%.
Is NDSN a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NDSN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 274.5 | -5.4% |
| Analysts Target Price | 274.5 | -5.4% |
| ValueRay Target Price | 319 | 9.9% |
NDSN Fundamental Data Overview February 07, 2026
P/E Forward = 25.1256
P/S = 5.6504
P/B = 5.1727
P/EG = 2.0179
Revenue TTM = 2.79b USD
EBIT TTM = 716.0m USD
EBITDA TTM = 866.5m USD
Long Term Debt = 1.68b USD (from longTermDebt, last quarter)
Short Term Debt = 338.3m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.98b USD (from netDebt column, last quarter)
Enterprise Value = 17.76b USD (15.77b + Debt 2.09b - CCE 108.4m)
Interest Coverage Ratio = 6.94 (Ebit TTM 716.0m / Interest Expense TTM 103.2m)
EV/FCF = 26.86x (Enterprise Value 17.76b / FCF TTM 661.1m)
FCF Yield = 3.72% (FCF TTM 661.1m / Enterprise Value 17.76b)
FCF Margin = 23.68% (FCF TTM 661.1m / Revenue TTM 2.79b)
Net Margin = 17.35% (Net Income TTM 484.5m / Revenue TTM 2.79b)
Gross Margin = 55.16% ((Revenue TTM 2.79b - Cost of Revenue TTM 1.25b) / Revenue TTM)
Gross Margin QoQ = 56.33% (prev 54.82%)
Tobins Q-Ratio = 3.00 (Enterprise Value 17.76b / Total Assets 5.92b)
Interest Expense / Debt = 1.14% (Interest Expense 23.8m / Debt 2.09b)
Taxrate = 17.09% (31.3m / 182.9m)
NOPAT = 593.6m (EBIT 716.0m * (1 - 17.09%))
Current Ratio = 1.64 (Total Current Assets 1.24b / Total Current Liabilities 758.3m)
Debt / Equity = 0.69 (Debt 2.09b / totalStockholderEquity, last quarter 3.04b)
Debt / EBITDA = 2.29 (Net Debt 1.98b / EBITDA 866.5m)
Debt / FCF = 3.00 (Net Debt 1.98b / FCF TTM 661.1m)
Total Stockholder Equity = 2.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 484.5m / Total Assets 5.92b)
RoE = 16.34% (Net Income TTM 484.5m / Total Stockholder Equity 2.97b)
RoCE = 15.41% (EBIT 716.0m / Capital Employed (Equity 2.97b + L.T.Debt 1.68b))
RoIC = 11.65% (NOPAT 593.6m / Invested Capital 5.10b)
WACC = 8.76% (E(15.77b)/V(17.87b) * Re(9.80%) + D(2.09b)/V(17.87b) * Rd(1.14%) * (1-Tc(0.17)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.99%
[DCF Debug] Terminal Value 76.06% ; FCFF base≈593.4m ; Y1≈620.7m ; Y5≈719.1m
Fair Price DCF = 160.1 (EV 10.90b - Net Debt 1.98b = Equity 8.92b / Shares 55.7m; r=8.76% [WACC]; 5y FCF grow 4.95% → 2.90% )
EPS Correlation: -35.58 | EPS CAGR: -47.51% | SUE: -4.0 | # QB: 0
Revenue Correlation: 58.80 | Revenue CAGR: 5.77% | SUE: -0.69 | # QB: 0
EPS next Quarter (2026-04-30): EPS=2.70 | Chg30d=-0.013 | Revisions Net=+0 | Analysts=10
EPS current Year (2026-10-31): EPS=11.17 | Chg30d=+0.017 | Revisions Net=+6 | Growth EPS=+9.1% | Growth Revenue=+4.2%
EPS next Year (2027-10-31): EPS=12.02 | Chg30d=+0.012 | Revisions Net=+2 | Growth EPS=+7.6% | Growth Revenue=+4.9%